ESO-T01

ESO-T01 is a third-generation, non-replicative, self-inactivating lentiviral vector designed to deliver a BCMA-targeted chimeric antigen receptor (CAR) gene directly into patients’ T cells in vivo. Unlike traditional ex vivo CAR-T therapies, ESO-T01 is administered as an “off-the-shelf” single intravenous dose that reprograms the patient’s own T cells within their body to express the anti-BCMA CAR. This approach eliminates the need for lymphodepletion and complex cell manufacturing processes. The therapy leverages EsoBiotec’s ENaBL platform technology to achieve immune-shielded delivery and robust in vivo transduction of T cells. ESO-T01 is being developed primarily for relapsed/refractory multiple myeloma and has shown promising early safety and efficacy signals in phase 1 clinical trials, with potential expansion into autoimmune diseases.

Other names

in vivo BCMA CAR-T